Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1288

1.

Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.

Noordijk EM, Carde P, Dupouy N, Hagenbeek A, Krol AD, Kluin-Nelemans JC, Tirelli U, Monconduit M, Thomas J, Eghbali H, Aleman BM, Bosq J, Vovk M, Verschueren TA, Pény AM, Girinsky T, Raemaekers JM, Henry-Amar M.

J Clin Oncol. 2006 Jul 1;24(19):3128-35. Epub 2006 Jun 5.

PMID:
16754934
2.

Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.

Fermé C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, Girinsky T, Brice P, van't Veer MB, Walewski JA, Lederlin P, Tirelli U, Carde P, Van den Neste E, Gyan E, Monconduit M, Diviné M, Raemaekers JM, Salles G, Noordijk EM, Creemers GJ, Gabarre J, Hagenbeek A, Reman O, Blanc M, Thomas J, Vié B, Kluin-Nelemans JC, Viseu F, Baars JW, Poortmans P, Lugtenburg PJ, Carrie C, Jaubert J, Henry-Amar M; EORTC-GELA H8 Trial.

N Engl J Med. 2007 Nov 8;357(19):1916-27.

3.

Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma.

Vassilakopoulos TP, Angelopoulou MK, Siakantaris MP, Kontopidou FN, Dimopoulou MN, Kokoris SI, Kyrtsonis MC, Tsaftaridis P, Karkantaris C, Anargyrou K, Boutsis DE, Variamis E, Michalopoulos T, Boussiotis VA, Panayiotidis P, Papavassiliou C, Pangalis GA.

Int J Radiat Oncol Biol Phys. 2004 Jul 1;59(3):765-81.

PMID:
15183480
4.

European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease.

Wilder RB, Schlembach PJ, Jones D, Chronowski GM, Ha CS, Younes A, Hagemeister FB, Barista I, Cabanillas F, Cox JD.

Cancer. 2002 Mar 15;94(6):1731-8.

5.

MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.

Gobbi PG, Broglia C, Levis A, La Sala A, Valentino F, Chisesi T, Sacchi S, Corbella F, Cavanna L, Iannitto E, Pavone V, Molica S, Corazza GR, Federico M.

Clin Cancer Res. 2006 Jan 15;12(2):529-35.

6.

Impact of chest wall and lung invasion on outcome of stage I-II Hodgkin's lymphoma after combined modality therapy.

Hodgson DC, Tsang RW, Pintilie M, Sun A, Wells W, Crump M, Gospodarowicz MK.

Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1374-81.

PMID:
14630276
7.

[Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].

Niu Y, Shi YK, He XH, Feng FY, Zhou LQ, Gu DZ.

Zhonghua Zhong Liu Za Zhi. 2008 Aug;30(8):630-4. Chinese.

PMID:
19102946
8.

Survival and late effects in children with Hodgkin's lymphoma treated with MOPP/ABV and low-dose, extended-field irradiation.

Chow LM, Nathan PC, Hodgson DC, Jenkin D, Weitzman S, Grant RM, Manson D, Bross A, Doyle JJ, Danjoux C, Greenberg ML.

J Clin Oncol. 2006 Dec 20;24(36):5735-41.

PMID:
17179107
9.

Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma.

Aleman BM, Raemaekers JM, Tomiŝiĉ R, Baaijens MH, Bortolus R, Lybeert ML, van der Maazen RW, Girinsky T, Demeestere G, Lugtenburg P, Lievens Y, de Jong D, Pinna A, Henry-Amar M; European Organization for Research and Treatment of Cancer (EORTC) Lymphoma Group.

Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):19-30. Epub 2006 Nov 9.

PMID:
17097834
10.

Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkin's disease. EORTC Lymphoma Cooperative Group. Groupe Pierre-et-Marie-Curie.

Noordijk EM, Carde P, Mandard AM, Mellink WA, Monconduit M, Eghbali H, Tirelli U, Thomas J, Somers R, Dupouy N, et al.

Ann Oncol. 1994;5 Suppl 2:107-12.

PMID:
7515643
11.

Involved-field radiotherapy for advanced Hodgkin's lymphoma.

Aleman BM, Raemaekers JM, Tirelli U, Bortolus R, van 't Veer MB, Lybeert ML, Keuning JJ, Carde P, Girinsky T, van der Maazen RW, Tomsic R, Vovk M, van Hoof A, Demeestere G, Lugtenburg PJ, Thomas J, Schroyens W, De Boeck K, Baars JW, Kluin-Nelemans JC, Carrie C, Aoudjhane M, Bron D, Eghbali H, Smit WG, Meerwaldt JH, Hagenbeek A, Pinna A, Henry-Amar M; European Organization for Research and Treatment of Cancer Lymphoma Group.

N Engl J Med. 2003 Jun 12;348(24):2396-406.

12.

ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.

Gobbi PG, Levis A, Chisesi T, Broglia C, Vitolo U, Stelitano C, Pavone V, Cavanna L, Santini G, Merli F, Liberati M, Baldini L, Deliliers GL, Angelucci E, Bordonaro R, Federico M; Intergruppo Italiano Linfomi.

J Clin Oncol. 2005 Dec 20;23(36):9198-207. Epub 2005 Sep 19.

PMID:
16172458
13.

Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.

Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M, Boissevain F, De Wit M, Mezger J, Duhmke E, Willich N, Muller RP, Schmidt BF, Renner H, Muller-Hermelink HK, Pfistner B, Wolf J, Hasenclever D, Loffler M, Diehl V; German Hodgkin's Lymphoma Study Group.

J Clin Oncol. 2003 Oct 1;21(19):3601-8. Epub 2003 Aug 11.

PMID:
12913100
14.

Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA).

Fermé C, Mounier N, Casasnovas O, Brice P, Divine M, Sonet A, Bouafia F, Bastard-Stamatoullas A, Bordessoule D, Voillat L, Reman O, Blanc M, Gisselbrecht C; Groupe d'Etude des Lymphomes de l'Adulte.

Blood. 2006 Jun 15;107(12):4636-42. Epub 2006 Feb 14.

15.

Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.

Montoto S, Camós M, López-Guillermo A, Bosch F, Cervantes F, Blandé J, Esteve J, Cobo F, Nomdedeu B, Campo E, Montserrat E.

Cancer. 2000 May 1;88(9):2142-8.

PMID:
10813727
16.

Radiotherapy alone for lymphocyte-predominant Hodgkin's disease.

Schlembach PJ, Wilder RB, Jones D, Ha CS, Fayad LE, Younes A, Hagemeister F, Hess M, Cabanillas F, Cox JD.

Cancer J. 2002 Sep-Oct;8(5):377-83.

PMID:
12416895
17.

Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi.

Chisesi T, Bellei M, Luminari S, Montanini A, Marcheselli L, Levis A, Gobbi P, Vitolo U, Stelitano C, Pavone V, Merli F, Liberati M, Baldini L, Bordonaro R, Pesce EA, Federico M.

J Clin Oncol. 2011 Nov 10;29(32):4227-33. doi: 10.1200/JCO.2010.30.9799. Epub 2011 Oct 11.

PMID:
21990405
18.

Analysis of treatment results in advanced Hodgkin's disease: the case for adjuvant radiotherapy.

Dyduch M, Skolyszewski J, Korzeniowski S, Sokolowski A.

Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):634-43.

PMID:
12788168
19.

Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin's disease: results of the groupe d'études des lymphomes de l'Adulte H89 trial.

Fermé C, Sebban C, Hennequin C, Diviné M, Lederlin P, Gabarre J, Ferrant A, Caillot D, Bordessoule D, Brice P, Moullet I, Berger F, Lepage E.

Blood. 2000 Apr 1;95(7):2246-52.

20.

Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987.

Tubiana M, Henry-Amar M, Carde P, Burgers JM, Hayat M, Van der Schueren E, Noordijk EM, Tanguy A, Meerwaldt JH, Thomas J, et al.

Blood. 1989 Jan;73(1):47-56.

Supplemental Content

Support Center